Regulating medicines in Europe: The European Medicines Agency, marketing authorisation, transparency and pharmacovigilance

17Citations
Citations of this article
56Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Following a review process lasting almost four years, and culminating in several pieces of new European legislation, adjustments have been made to the European Union's (EU) regulatory framework for pharmaceuticals. The European Commission laid out its priorities for the review as: simplifying the authorisation system, ensuring a high quality of public health, completing the internal market in medicines, and preparing for the enlargement of the Union. Amongst the most important changes brought about by the new rules are those relating to the European drug approval procedures, the functions and operational transparency of the European Medicines Agency (EMEA), and the EU's pharmacovigilance system. This article provides a brief examination of key elements of these changes, and considers the extent to which they serve the goal of improved public health protection within the EU.

Cite

CITATION STYLE

APA

Permanand, G., Mossialos, E., & McKee, M. (2006). Regulating medicines in Europe: The European Medicines Agency, marketing authorisation, transparency and pharmacovigilance. Clinical Medicine, Journal of the Royal College of Physicians of London. Royal College of Physicians. https://doi.org/10.7861/clinmedicine.6-1-87

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free